Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6902569 | 0.87 | CYP2D6 (0.38) | CYP2D6MAPTPTGS1PTGS2OPRK1 | |
| SCHEMBL1237594 | 0.85 | CYP2D6 (0.41) | CYP2D6MAPTACEPTGS1PTGS2 | |
| SCHEMBL6898594 | 0.82 | MAPT (0.39) | CYP2D6MAPTACEPTGS1PTGS2 | |
| SCHEMBL1237574 | 0.80 | CYP2D6 (0.47) | CYP2D6MAPTACEKMT2A | |
| SCHEMBL6907464 | 0.79 | CYP2D6 (0.46) | CYP2D6MAPTACEHTTKMT2A | |
| SCHEMBL913008 | 0.79 | CYP2D6 (0.39) | CYP2D6MAPT | |
| SCHEMBL7063108 | 0.79 | CYP2D6 (0.46) | CYP2D6MAPTACEHTTKMT2A | |
| SCHEMBL1238390 | 0.78 | CYP2D6 (0.43) | CYP2D6MAPTPTGS1PTGS2OPRK1 | |
| SCHEMBL6902894 | 0.78 | CYP2D6 (0.38) | CYP2D6MAPTPTGS1PTGS2OPRK1 | |
| SCHEMBL1238426 | 0.78 | CYP2D6 (0.38) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833481-B2 | Catalytic dehydrative isomerization | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2004-12-21 | — | — | US | disclosed |
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | TAKASAGO INTERNATIONAL CORPORATION | 2003-06-12 | — | — | US | disclosed |
| EP-1316541-A1 | Process for producing 2-alkyl-2-cyclopentenones | Takasago International Corporation (JP) | 2003-06-04 | — | — | EP | disclosed |
| CN-1421429-A | Process for producing 2-alkyl-2-cyclopentenone | TAKASAGO PERFUMERY CO LTD (JP) | 2003-06-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109755-A1 | Process for producing 2-alkyl-2cyclopentenones | HSD3B2, DHPS, HSD3B1 | CYP2D6 129/4885MAPT 4641/4885ACE 4306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.